The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
One task, one interaction, one pair, experts advocate
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Subscribe To Our Newsletter & Stay Updated
